Pediatric Gastroenterology, Department of Pediatrics, Center for Liver, Digestive, and Metabolic Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Gut. 2010 Mar;59(3):373-80. doi: 10.1136/gut.2009.183921. Epub 2009 Nov 5.
Several conditions that delay gastrointestinal transit are associated with unconjugated hyperbilirubinaemia. We hypothesised that the gastrointestinal transit time is directly related to plasma unconjugated bilirubin (UCB) concentrations, and that this relationship can be used to develop a new therapeutic strategy for severe unconjugated hyperbilirubinaemia in the Gunn rat model.
Gunn rats received, for various time periods, oral polyethylene glycol (PEG) with or without conventional phototherapy treatment to accelerate, or oral loperamide to delay gastrointestinal transit. Gastrointestinal transit time and UCB concentrations in plasma, faeces, intestinal content and bile were determined. Results Within 36 h, PEG administration accelerated gastrointestinal transit by 45% and simultaneously decreased plasma UCB concentrations by 23% (each p<0.001). The decrease in plasma UCB coincided with an increased small intestinal UCB content (+340%, p<0.05) and an increased faecal UCB excretion (+153%, p<0.05). After 2 weeks, PEG decreased plasma UCB by 41% as single treatment, and by 62% if combined with phototherapy (each p<0.001). Loperamide delayed gastrointestinal transit by 57% and increased plasma UCB by 30% (each p<0.001). Dose-response experiments showed a strong, linear relation between the gastrointestinal transit time and plasma UCB concentrations (r=0.87, p<0.001).
Gastrointestinal transit time and plasma UCB concentrations are linearly related in Gunn rats. This relationship can be exploited by pharmacologically accelerating the gastrointestinal transit, which increases transmucosal UCB diffusion and thereby effectively treats unconjugated hyperbilirubinaemia. Present results support the feasibility of PEG treatment, either solitary or combined with phototherapy, in patients with severe unconjugated hyperbilirubinaemia.
几种延迟胃肠道转运的情况与未结合高胆红素血症有关。我们假设胃肠道转运时间与血浆未结合胆红素(UCB)浓度直接相关,并且这种关系可用于开发 Gunn 大鼠模型中严重未结合高胆红素血症的新治疗策略。
Gunn 大鼠接受了不同时间的口服聚乙二醇(PEG)加或不加常规光疗治疗以加速胃肠道转运,或口服洛哌丁胺以延迟胃肠道转运。测定胃肠道转运时间和血浆、粪便、肠内容物和胆汁中的 UCB 浓度。
在 36 小时内,PEG 给药使胃肠道转运加速了 45%,同时使血浆 UCB 浓度降低了 23%(均 p<0.001)。血浆 UCB 的减少与小肠 UCB 含量增加(+340%,p<0.05)和粪便 UCB 排泄增加(+153%,p<0.05)相一致。2 周后,PEG 单独治疗使血浆 UCB 降低 41%,与光疗联合治疗降低 62%(均 p<0.001)。洛哌丁胺使胃肠道转运延迟 57%,血浆 UCB 增加 30%(均 p<0.001)。剂量反应实验显示胃肠道转运时间和血浆 UCB 浓度之间存在很强的线性关系(r=0.87,p<0.001)。
在 Gunn 大鼠中,胃肠道转运时间和血浆 UCB 浓度呈线性相关。这种关系可以通过药理学加速胃肠道转运来利用,从而增加跨黏膜 UCB 扩散,从而有效地治疗未结合高胆红素血症。目前的结果支持在严重未结合高胆红素血症患者中使用 PEG 治疗,无论是单独使用还是与光疗联合使用。